Your browser doesn't support javascript.
loading
Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.
Sharma, Rupali; Earla, Bhargav; Baidoo, Kwamena E; Zeiger, Martha A; Madigan, James P; Escorcia, Freddy E; Sadowski, Samira M.
Afiliación
  • Sharma R; Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Earla B; Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Baidoo KE; UAB Heersink School of Medicine, Birmingham, Alabama.
  • Zeiger MA; Molecular Imaging Branch, Radiation Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Madigan JP; Office of Surgeon Scientists Programs, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Escorcia FE; Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Sadowski SM; Molecular Imaging Branch, Radiation Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Mol Cancer Ther ; 22(9): 1052-1062, 2023 09 05.
Article en En | MEDLINE | ID: mdl-37487000

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumores Neuroendocrinos / Tumores Neuroectodérmicos Primitivos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumores Neuroendocrinos / Tumores Neuroectodérmicos Primitivos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos